ERBB2 and non-small cell lung carcinoma: After the use of trastuzumab deruxtecan in patients with metastatic HER2-mutated NSCLC who were not responding to standard therapy, 55% of patients showed proven objective efficacy with a median duration of efficacy of 9.3 months, median progression-free survival of 8.2 months, and median overall survival of 17.8 months (Li et al., 2022).